Albert David Limited
NSE: ALBERTDAVD
NSE
905.60
2.30 (0.25%)
Prev Close
903.3
Open Price
900
Volume
4,923
Today Low / High
893 / 912
52 WK Low / High
762.6 / 1753.95
Range
860 - 951
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 905.6, with a change of 2.3 (0.25462%). The expected target range on the NSE is between 860 - 951. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
11 Jul
900.00
0.62%
10 Jul
923.75
-2.21%
09 Jul
923.55
-0.25%
08 Jul
928.30
-0.68%
07 Jul
947.65
-2.54%
04 Jul
909.00
4.13%
03 Jul
895.25
-0.64%
02 Jul
892.00
0.35%
01 Jul
835.10
5.56%
30 Jun
838.95
-0.34%
27 Jun
845.50
-1.25%
26 Jun
852.15
-1.10%
25 Jun
847.65
0.04%
24 Jun
851.45
-1.03%
23 Jun
841.40
-0.31%
20 Jun
841.75
0.53%
19 Jun
845.20
0.09%
18 Jun
852.10
-0.80%
17 Jun
864.85
-1.16%
16 Jun
871.95
-1.02%
Albert David Limited Graph
Albert David Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Albert David Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 905.60, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 905.60 | 914.66 | 823.19 - 1,006.12 |
| 923.71 | 738.97 - 1,108.45 | ||
| 932.77 | 652.94 - 1,212.60 | ||
| Bearish Scenario | 905.60 | 896.54 | 806.89 - 986.20 |
| 887.49 | 709.99 - 1,064.99 | ||
| 878.43 | 614.90 - 1,141.96 |
Overview of Albert David Limited
ISIN
INE155C01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
7,384
Market Cap
5,168,404,096
Last Dividend
11.5
Official Website
IPO Date
2016-06-14
DCF Diff
-430.64
DCF
1,336
Financial Ratios Every Investor Needs
Stock Dividend of ALBERTDAVD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 5 | 5 | 2025-07-25 | 2025-08-07 | |
| 2024-08-02 | August 02, 24 | 11.5 | 11.5 | 2024-08-02 | 2024-09-08 | |
| 2023-08-02 | August 02, 23 | 9 | 9 | 2023-08-03 | 2023-09-09 | |
| 2022-08-01 | August 01, 22 | 9 | 9 | 2022-08-02 | 2022-09-08 | |
| 2021-09-06 | September 06, 21 | 6 | 6 | 2021-09-07 | 2021-10-14 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 345.77 Cr | 116.28 Cr | 229.48 Cr | 0.6637 | 0.00 Cr | 0.00 Cr | 120.46 Cr | 17.20 Cr | 30.14 | 3.03 Cr | 0.0497 |
| 2024-03-31 | 360.26 Cr | 128.40 Cr | 231.86 Cr | 0.6436 | 1.95 Cr | 89.14 Cr | 133.45 Cr | 75.42 Cr | 132.15 | 104.54 Cr | 0.2093 |
| 2023-03-31 | 341.56 Cr | 123.09 Cr | 218.48 Cr | 0.6396 | 1.90 Cr | 49.74 Cr | 36.24 Cr | 36.17 Cr | 63.39 | 59.87 Cr | 0.1059 |
| 2022-03-31 | 312.43 Cr | 117.52 Cr | 194.91 Cr | 0.6239 | 1.60 Cr | 35.56 Cr | 31.99 Cr | 35.26 Cr | 61.78 | 56.78 Cr | 0.1129 |
| 2021-03-31 | 246.31 Cr | 88.03 Cr | 158.29 Cr | 0.6426 | 1.53 Cr | 28.94 Cr | 10.92 Cr | 22.14 Cr | 38.80 | 36.46 Cr | 0.0899 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.69 Cr | 511.42 Cr | 118.93 Cr | 392.4834 Cr | 12.32 Cr | 10.62 Cr | 63.90 Cr | 99.44 Cr | 0.00 Cr | 0.00 Cr | 56.05 Cr | 104.1800 Cr |
| 2024-03-31 | 5.44 Cr | 497.99 Cr | 115.01 Cr | 382.9810 Cr | 3.32 Cr | -2.11 Cr | 43.61 Cr | 88.28 Cr | 3.24 Cr | 0.00 Cr | 32.84 Cr | 99.0476 Cr |
| 2023-03-31 | 1.45 Cr | 423.39 Cr | 111.83 Cr | 311.5676 Cr | 5.32 Cr | 3.87 Cr | 50.68 Cr | 80.28 Cr | 58.73 Cr | -3.97 Cr | 29.88 Cr | 98.9375 Cr |
| 2022-03-31 | 2.28 Cr | 402.84 Cr | 123.37 Cr | 279.4711 Cr | 5.66 Cr | 3.39 Cr | 39.18 Cr | 84.62 Cr | 70.12 Cr | 0.00 Cr | 55.55 Cr | 108.9432 Cr |
| 2021-03-31 | 5.08 Cr | 341.40 Cr | 97.02 Cr | 244.3820 Cr | 1.62 Cr | -3.46 Cr | 35.75 Cr | 83.24 Cr | 44.63 Cr | 0.00 Cr | 28.86 Cr | 80.6091 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -28.4358 Cr | 23.3013 Cr | 0.1103 Cr | -43.2917 Cr | -5.0216 Cr | 0.4173 Cr | -14.8559 Cr | 17.2008 Cr | -1.0436 Cr | -6.5481 Cr | -20.2899 Cr |
| 2024-03-31 | 45.5022 Cr | -39.1078 Cr | -8.2699 Cr | 34.6282 Cr | 3.9935 Cr | 5.4389 Cr | -10.8740 Cr | 75.4201 Cr | -1.8690 Cr | -5.1691 Cr | 7.0704 Cr |
| 2023-03-31 | 10.5150 Cr | -4.9952 Cr | -6.3622 Cr | 5.2781 Cr | -0.8308 Cr | 1.4454 Cr | -5.2369 Cr | 50.7354 Cr | 0.2032 Cr | -5.1498 Cr | -11.5033 Cr |
| 2022-03-31 | 40.3647 Cr | -39.6973 Cr | -4.8801 Cr | 29.2833 Cr | -4.1323 Cr | -1.4895 Cr | -11.0814 Cr | 47.2976 Cr | -1.1557 Cr | -3.4358 Cr | -3.4311 Cr |
| 2021-03-31 | 36.6107 Cr | -36.6844 Cr | -1.7050 Cr | 34.9786 Cr | -1.7741 Cr | 4.6428 Cr | -1.6321 Cr | 27.4436 Cr | -1.2163 Cr | -0.0402 Cr | 6.9748 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 74.89 Cr | 29.33 Cr | 45.57 Cr | 0.6084 | 22.89 Cr | -10.33 Cr | -18.10 | -4.82 Cr | -0.1379 |
| 2024-12-31 | 83.08 Cr | 26.34 Cr | 56.75 Cr | 0.6830 | -1.03 Cr | -9.39 Cr | -16.45 | -8.34 Cr | -0.1130 |
| 2024-09-30 | 98.44 Cr | 30.32 Cr | 68.12 Cr | 0.6920 | 4.55 Cr | 18.07 Cr | 31.67 | 26.86 Cr | 0.1836 |
| 2024-06-30 | 89.36 Cr | 30.30 Cr | 59.06 Cr | 0.6609 | 30.69 Cr | 18.84 Cr | 33.02 | 23.94 Cr | 0.2109 |
| 2024-03-31 | 89.06 Cr | 54.20 Cr | 34.86 Cr | 0.3914 | 7.74 Cr | 12.91 Cr | 22.63 | 20.01 Cr | 0.1450 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.69 Cr | 242.21 Cr | 243.91 Cr | 27.37 Cr | 63.90 Cr | 354.05 Cr | 99.44 Cr | 511.42 Cr | 118.93 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 317.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -413.24 Cr |
| 2024-09-30 | 3.70 Cr | 318.59 Cr | 322.29 Cr | 0.00 Cr | 47.48 Cr | 416.15 Cr | 95.32 Cr | 535.33 Cr | 122.10 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 285.23 Cr | 0.00 Cr | 0.00 Cr | 285.23 Cr | 0.00 Cr | 0.00 Cr | -382.98 Cr |
| 2024-03-31 | 31.16 Cr | 254.30 Cr | 285.46 Cr | 29.33 Cr | 43.61 Cr | 371.63 Cr | 88.28 Cr | 497.99 Cr | 115.01 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -10.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | -9.39 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 18.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 18.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 12.91 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,672.00 | ₹4,011,596,160,000.00 | ₹1,298,300.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,835.00 | ₹1,814,480,615,000.00 | ₹224,031.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,314.20 | ₹1,121,674,419,000.00 | ₹344,196.00 |
| Mankind Pharma Limited | MANKIND | ₹2,578.30 | ₹1,064,138,561,908.00 | ₹2,780,363.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,254.70 | ₹1,044,010,449,778.00 | ₹895,308.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹979.60 | ₹985,702,908,000.00 | ₹921,030.00 |
| Lupin Limited | LUPIN | ₹1,894.70 | ₹865,339,805,200.00 | ₹1,511,045.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,124.80 | ₹653,286,089,600.00 | ₹1,058,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,181.10 | ₹615,508,601,100.00 | ₹15,678,334.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,806.70 | ₹574,713,085,500.00 | ₹183,070.00 |
| Laurus Labs Limited | LAURUSLABS | ₹790.20 | ₹426,117,720,600.00 | ₹1,475,669.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,017.95 | ₹389,434,085,794.00 | ₹322,114.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,449.60 | ₹367,769,318,400.00 | ₹119,065.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,626.50 | ₹328,081,368,000.00 | ₹236,895.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,757.10 | ₹285,491,850,900.00 | ₹3,159,181.00 |
| Piramal Enterprises Limited | PEL | ₹1,217.50 | ₹275,980,465,000.00 | ₹2,508,249.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,608.60 | ₹251,036,507,400.00 | ₹444,444.00 |
| Eris Lifesciences Limited | ERIS | ₹1,709.80 | ₹232,869,630,600.00 | ₹106,770.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,241.50 | ₹231,037,500,000.00 | ₹20,847.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹976.60 | ₹191,963,425,800.00 | ₹60,016.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,165.70 | ₹185,673,861,700.00 | ₹144,076.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹961.80 | ₹172,267,998,000.00 | ₹1,353,979.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,301.00 | ₹157,820,599,900.00 | ₹74,663.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,023.30 | ₹153,794,472,610.00 | ₹35,929.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹469.00 | ₹113,800,036,000.00 | ₹331,193.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,755.50 | ₹95,537,846,700.00 | ₹23,112.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹896.75 | ₹87,693,989,575.00 | ₹154,034.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹927.20 | ₹84,036,419,664.00 | ₹291,915.00 |
| Strides Pharma Science Limited | STAR | ₹887.80 | ₹81,822,045,060.00 | ₹428,094.00 |
| FDC Limited | FDC | ₹501.35 | ₹81,624,793,500.00 | ₹72,209.00 |
| Suven Life Sciences Limited | SUVEN | ₹276.63 | ₹60,325,810,620.00 | ₹285,602.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹159.34 | ₹51,709,335,480.00 | ₹1,252,722.00 |
| Innova Captab Limited | INNOVACAP | ₹875.40 | ₹50,094,703,722.00 | ₹46,543.00 |
| Sequent Scientific Limited | SEQUENT | ₹184.32 | ₹46,136,217,600.00 | ₹343,582.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹473.60 | ₹43,225,472,000.00 | ₹158,284.00 |
| Hikal Limited | HIKAL | ₹340.50 | ₹41,983,990,500.00 | ₹164,468.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,526.20 | ₹41,780,821,800.00 | ₹17,230.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹590.85 | ₹41,599,266,930.00 | ₹17,355.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.30 | ₹36,431,529,530.00 | ₹55,088.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.05 | ₹35,002,035,900.00 | ₹50,065.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹62.67 | ₹34,340,277,180.00 | ₹1,978,828.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹664.85 | ₹32,014,522,050.00 | ₹589,436.00 |
| Indoco Remedies Limited | INDOCO | ₹326.45 | ₹30,114,326,955.00 | ₹174,646.00 |
| Alembic Limited | ALEMBICLTD | ₹117.26 | ₹30,110,257,203.00 | ₹332,328.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹91.18 | ₹26,763,791,860.00 | ₹1,225,212.00 |
Key Executives
Head of Sales Training
Mr. Siddesh Rege
Gender: male
Year Born:
Chief Financial Officer & Chief Investor Relations Officer
Mr. Ranadeep Bhattacharya
Gender: male
Year Born: 1971
Executive Chairman
Mr. Arun Kumar Kothari
Gender: male
Year Born: 1953
General Manager of Sales & Marketing
Dr. Nandraj Patil
Gender: Not Specified
Year Born:
Plant Head - Kolkata
Mr. Santanu Bhattacharya
Gender: male
Year Born: 1969
Head of Operations - Ghaziabad
Mr. Chandra B. Thakur
Gender: male
Year Born:
Corporate Head of Human Resource
Mr. Adi Joyti Chattopadhyay
Gender: male
Year Born: 1962
MD, Chief Executive Officer & Director
Mr. Umesh Manohar Kunte
Gender: male
Year Born: 1969
FAQs about Albert David Limited
Who is the CEO of the company?
The CEO is Umesh Manohar Kunte.
What is the current market price of the stock?
The current price is ₹905.60.
What is the 52-week price range?
The range is ₹762.6-1753.95.
What is the market capitalization of the company?
The market capitalization is ₹516.84 crores.
What is the dividend yield?
The dividend yield is 1.27%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 30.04.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Albert David Limited (ISIN: INE155C01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹516.84 crores and an average daily volume of 7,384 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹11.5.